Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Monoclonal antibody thera… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes

Artikel i vetenskaplig tidskrift
Författare Jan Lycke
Publicerad i Therapeutic Advances in Neurological Disorders
Volym 8
Nummer/häfte 6
Sidor 274-293
ISSN 1756-2856
Publiceringsår 2015
Publicerad vid Institutionen för neurovetenskap och fysiologi
Sidor 274-293
Språk en
Länkar dx.doi.org/10.1177/1756285615605429
Ämnesord antibodies, autoimmunity, monoclonal, multiple sclerosis, therapy, progressive multifocal leukoencephalopathy, experimental autoimmune, encephalomyelitis, placebo-controlled trial, central-nervous-system, natalizumab treatment interruption, therapeutic lymphocyte depletion, alpha-4 integrin expression, controlled phase-3 trial, high-yield, process, double-blind, Neurosciences & Neurology
Ämneskategorier Neurovetenskap, Neurologi

Sammanfattning

Monoclonal antibody (mAb) therapies for relapsing-remitting multiple sclerosis (MS) target immune cells or other molecules involved in pathogenic pathways with extraordinary specificity. Natalizumab and alemtuzumab are the only two currently approved mAbs for the treatment of MS, having demonstrated significant reduction in clinical and magnetic resonance imaging disease activity and disability in clinical studies. Ocrelizumab and daclizumab are in the late stages of phase III trials, and several other mAbs are in the early stages of clinical evaluation. mAbs have distinct structural characteristics (e.g. chimeric, humanized, fully human) and unique targets (e.g. blocking interactions, induction of signal transduction by receptor binding, complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity) conferring different mechanisms of action in MS. Because of these differences, mAbs for MS do not constitute a single treatment class; each must be considered individually when selecting appropriate therapy. Furthermore, in reviewing the data from clinical studies of mAbs, attention should be drawn to use of different comparators (e.g. placebo or interferon -1a) and study designs. Each mAb treatment has a unique administration schedule. In the decision to select the appropriate treatment for each individual MS patient, careful review of the benefits relative to risks of mAbs is balanced against the risk of development of MS-associated disability.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?